{"schema_version":"secwatch.filing_event.v1","accession":"0001453687-22-000136","form_type":"8-K","ticker":"RNAC","cik":"0001453687","company_name":"Cartesian Therapeutics, Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.720711+00:00","generated_at":"2026-06-22T08:43:49.165100+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Selecta Q3 net loss narrows to $7.9M; cash runway to mid-2024","bullets":["Net loss of $7.9M ($0.05 per share) vs $17.9M loss in Q3 2021; collaboration revenue $20.7M.","Cash, equivalents & securities total $148.0M as of Sep 30, 2022; expected runway into mid-2024.","Received $10M milestone from Sobi for DISSOLVE II enrollment and $6M from Sarepta for DMD/LGMD.","Topline data from Phase 3 DISSOLVE (SEL-212 for chronic gout) expected in Q1 2023.","Phase 1 trial of SEL-302 (MMA gene therapy) on track to begin Q4 2022; IL-2 and IgA protease candidates by year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001453687-22-000136","json":"https://secwatch.observer/filing/0001453687-22-000136.json","markdown":"https://secwatch.observer/filing/0001453687-22-000136.md","text":"https://secwatch.observer/filing/0001453687-22-000136.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453687/000145368722000136/0001453687-22-000136-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453687/000145368722000136/selb-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T08:43:49.165100+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ee46a5074f33cd388c09a8b983f9ff73175b8099","claim":"Cartesian Therapeutics, Inc. reported financial results for quarter ended September 30, 2022.","evidence_excerpt":"Selecta Biosciences, Inc. announced its financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368722000136/0001453687-22-000136-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}